Reoccurring disappointment in development portfolios-why it happens and how to mitigate it.
Gary Summers
Advertisement
Articles by Gary Summers
Advertisement
Latest Updated Articles
Product Development: The Optimizer’s CursePublished: September 19th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
